Beliefs around luck : confirming the empirical conceptualization of beliefs around luck and the development of the Darke and Freedman beliefs around luck scale

The current study developed a multi-dimensional measure of beliefs around luck. Two studies introduced the Darke and Freedman beliefs around luck scale where the scale showed a consistent 4 component model (beliefs in luck, rejection of luck, being lucky, and being unlucky) across two samples (n = 250; n = 145). The scales also show adequate reliability statistics and validity by ways of comparison with other measures of beliefs around luck, peer and family ratings and expected associations with measures of personality, individual difference and well-being variables

Kinematics of the Circumgalactic Medium of a z=0.77z = 0.77 Galaxy from MgII Tomography

Galaxy evolution is thought to be driven in large part by the flow of gas between galaxies and the circumgalactic medium (CGM), a halo of metal-enriched gas extending out to $\gtrsim100$ kpc from each galaxy. Studying the spatial structure of the CGM holds promise for understanding these gas flow mechanisms; however, the common method using background quasar sightlines provides minimal spatial information. Recent works have shown the utility of extended background sources such as giant gravitationally lensed arcs. Using background lensed arcs from the CSWA 38 lens system, we continuously probed, at a resolution element of about 15 kpc$^2$, the spatial and kinematic distribution of MgII absorption in a star-forming galaxy at $z=0.77$ (stellar mass $\approx 10^{9.7}$ M$_\odot$, star formation rate $\approx 10$ M$_\odot$ yr$^{-1}$) at impact parameters $D=5-40$ kpc. Our results present an anisotropic, optically thick medium whose absorption strength decreases with increasing impact parameter, in agreement with the statistics towards quasars and other gravitational arcs. Furthermore, we detect low line-of-sight velocities ($v\approx-25-80$ km s$^{-1}$) and relatively high velocity dispersion ($\sigma\approx50\pm30$ km s$^{-1}$) in the MgII gas. These measures provide evidence of a mainly pressure-supported, metal-enriched diffuse gas recycling through the CGM rather than an active galactic outflow.Comment: 19 pages, 8 figures, 5 table

The structure function of semi-inclusive heavy flavour decays in field theory

We consider the decay of a heavy flavour into an inclusive hadronic state X of invariant mass m_X small with respect to its energy E_X, m_X << E_X. The electron spectrum and the hadronic mass distribution in semileptonic b -> u decays, or the photon spectrum in b -> s gamma decays, all require, close to their endpoints, a control over this region. This region is affected both by non-perturbative phenomena related to the Fermi motion of the heavy quark and by perturbative soft gluon radiation in the final state (Sudakov form factor).Fermi motion can be described by the shape function f (m*), which represents the distribution of the effective mass m* of the heavy quark at disintegration time. We perform a factorization with a simple technique in order to consistently separate perturbative from non-perturbative effects. We find that the shape function, contrary to naive expectations,is not a physical distribution, as it is affected by substantial regularization scheme effects, controlling even the leading, double-logarithmic term. It factorizes, however, the bulk of non-perturbative effects in lattice-like regularizations. Some non-perturbative effects are present in the coefficient function even at leading twist, but they are expected to be suppressed on physical grounds. Finally, we clarify a controversial factor of 2 in the evolution kernel of the shape function.Comment: 52 pages, 5 figures, LaTeX. More descriptive title. A few minor changes. To be published in Nucl. Phys.

Efficiently combining Machine Learning with OpenFOAM using SmartSim - Slides

Slides: 18th OpenFOAM Workshop - Efficiently combining Machine Learning with OpenFOAM using SmartSim1.

Paleoclimate Changes in the Pacific Northwest Over the Past 36,000 Years From Clumped Isotope Measurements and Model Analysis

Since the last glacial period, North America has experienced dramatic changes in regional climate, including the collapse of ice sheets and changes in precipitation. We use clumped isotope (∆47) thermometry and carbonate δ18O measurements of glacial and deglacial pedogenic carbonates from the Palouse Loess to provide constraints on hydroclimate changes in the Pacific Northwest. We also employ analysis of climate model simulations to help us further provide constraints on the hydroclimate changes in the Pacific Northwest. The coldest clumped isotope soil temperatures T(△47) (13.5 ± 1.9°C to 17.1 ± 1.7°C) occurred ∼34,000–23,000 years ago. Using a soil-to-air temperature transfer function, we estimate Last Glacial Maximum (LGM) mean annual air temperatures of ∼−5.5°C and warmest average monthly temperatures (i.e., mean summer air temperatures) of ∼4.4°C. These data indicate a regional warming of 16.4 ± 2.6°C from the LGM to the modern temperatures of 10.9°C, which was about 2.5–3 times the global average. Proxy data provide locality constraints on the boundary of the cooler anticyclone induced by LGM ice sheets, and the warmer cyclone in the Eastern Pacific Ocean. Climate model analysis suggests regional amplification of temperature anomalies is due to the proximal location of the study area to the Laurentide Ice Sheet margin and the impact of the glacial anticyclone on the region, as well as local albedo. Isotope-enabled model experiments indicate variations in water δ18O largely reflect atmospheric circulation changes and enhanced rainout upstream that brings more depleted vapor to the region during the LGM

The CCAAT displacement protein/cut homeodomain protein represses osteocalcin gene transcription and forms complexes with the retinoblastoma protein-related protein p107 and cyclin A

Developmental control of bone tissue-specific genes requires positive and negative regulatory factors to accommodate physiological requirements for the expression or suppression of the encoded proteins. Osteocalcin (OC) gene transcription is restricted to the late stages of osteoblast differentiation. OC gene expression is suppressed in nonosseous cells and osteoprogenitor cells and during the early proliferative stages of bone cell differentiation. The rat OC promoter contains a homeodomain recognition motif within a highly conserved multipartite promoter element (OC box I) that contributes to tissue-specific transcription. In this study, we demonstrate that the CCAAT displacement protein (CDP), a transcription factor related to the cut homeodomain protein in Drosophila melanogaster, may regulate bone-specific gene transcription in immature proliferating osteoblasts. Using gel shift competition assays and DNase I footprinting, we show that CDP/cut recognizes two promoter elements (TATA and OC box I) of the bone-related rat OC gene. Overexpression of CDP/cut in ROS 17/2.8 osteosarcoma cells results in repression of OC promoter activity; this repression is abrogated by mutating OC box I. Gel shift immunoassays show that CDP/cut forms a proliferation-specific protein/DNA complex in conjunction with cyclin A and p107, a member of the retinoblastoma protein family of tumor suppressors. Our findings suggest that CDP/cut may represent an important component of a cell signaling mechanism that provides cross-talk between developmental and cell cycle-related transcriptional regulators to suppress bone tissue-specific genes during proliferative stages of osteoblast differentiation

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers

Introduction Endocrine therapies target oestrogenic stimulation of breast cancer (BC) growth, but resistance remains problematic. Our aims in this study were (1) to identify genes most strongly associated with resistance to endocrine therapy by intersecting global gene transcription data from patients treated presurgically with the aromatase inhibitor anastrazole with those from MCF7 cells adapted to long-term oestrogen deprivation (LTED) (2) to assess the clinical value of selected genes in public clinical data sets and (3) to determine the impact of targeting these genes with novel agents. Methods Gene expression and Ki67 data were available from 69 postmenopausal women with oestrogen receptor–positive (ER+) early BC, at baseline and 2 weeks after anastrazole treatment, and from cell lines adapted to LTED. The functional consequences of target genes on proliferation, ER-mediated transcription and downstream cell signalling were assessed. Results By intersecting genes predictive of a poor change in Ki67 with those upregulated in LTED cells, we identified 32 genes strongly correlated with poor antiproliferative response that were associated with inflammation and/or immunity. In a panel of LTED cell lines, C-X-C chemokine receptor type 7 (CXCR7) and CXCR4 were upregulated compared to their wild types (wt), and CXCR7, but not CXCR4, was associated with reduced relapse-free survival in patients with ER+ BC. The CXCR4 small interfering RNA variant (siCXCR4) had no specific effect on the proliferation of wt-SUM44, wt-MCF7 and their LTED derivatives. In contrast, siCXCR7, as well as CCX733, a CXCR7 antagonist, specifically suppressed the proliferation of MCF7-LTED cells. siCXCR7 suppressed proteins associated with G1/S transition and inhibited ER transactivation in MCF7-LTED, but not wt-MCF7, by impeding association between ER and proline-, glutamic acid– and leucine-rich protein 1, an ER coactivator. Conclusions These data highlight CXCR7 as a potential therapeutic target warranting clinical investigation in endocrine-resistant BC

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

BACKGROUND: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. METHODS: The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine. Patients were assigned (1:1) to receive 3 months or 6 months of adjuvant oxaliplatin-containing chemotherapy. The chemotherapy regimens could consist of CAPOX (capecitabine and oxaliplatin) or FOLFOX (bolus and infused fluorouracil with oxaliplatin). The regimen was selected before randomisation in accordance with choices of the patient and treating physician. The primary study endpoint was disease-free survival and the non-inferiority margin was a hazard ratio of 1·13. The primary analysis was done in the intention-to-treat population and safety was assessed in patients who started study treatment. This trial is registered with ISRCTN, number ISRCTN59757862, and follow-up is continuing. FINDINGS: 6088 patients underwent randomisation between March 27, 2008, and Nov 29, 2013. The intended treatment was FOLFOX in 1981 patients and CAPOX in 4107 patients. 3044 patients were assigned to 3 month group and 3044 were assigned to 6 month group. Nine patients in the 3 month group and 14 patients in the 6 month group did not consent for their data to be used, leaving 3035 patients in the 3 month group and 3030 patients in the 6 month group for the intention-to-treat analyses. At the cutoff date for analysis, there had been 1482 disease-free survival events, with 740 in the 3 month group and 742 in the 6 month group. 3 year disease-free survival was 76·7% (95% CI 75·1-78·2) for the 3 month group and 77·1% (75·6-78·6) for the 6 month group, giving a hazard ratio of 1·006 (0·909-1·114, test for non-inferiority p=0·012), significantly below the non-inferiority margin. Peripheral neuropathy of grade 2 or worse was more common in the 6 month group (237 [58%] of 409 patients for the subset with safety data) than in the 3 month group (103 [25%] of 420) and was long-lasting and associated with worse quality of life. 1098 serious adverse events were reported (492 reports in the 3 month group and 606 reports in the 6 month group) and 32 treatment-related deaths occurred (16 in each group). INTERPRETATION: In the whole study population, 3 months of oxaliplatin-containing adjuvant chemotherapy was non-inferior to 6 months of the same therapy for patients with high-risk stage II and stage III colorectal cancer and was associated with reduced toxicity and improved quality of life. Despite the fact the study was underpowered, these data suggest that a shorter duration leads to similar survival outcomes with better quality of life and thus might represent a new standard of care. FUNDING: Medical Research Council, Swedish Cancer Society, NETSCC, and Cancer Research UK